Jorge Eduardo Cortes

List of Publications by Citations

570 papers	45,469 citations	109 h-index	195 g-index
579 ext. papers	52,094 ext. citations	5.9 avg, IF	7.19 L-index

#	Paper	IF	Citations
570	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2006**, 354, 2531-41	59.2	1414
569	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, **2013**, 122, 872-84	2.2	1413
568	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *New England Journal of Medicine*, **2010**, 362, 2260-70	59.2	1197
567	Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *New England Journal of Medicine*, **2006**, 354, 2542-51	59.2	1133
566	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *Journal of Clinical Oncology*, **2009**, 27, 6041-51	2.2	1019
565	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*, **2006**, 108, 1809-20	2.2	998
564	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*, **2006**, 108, 28-37	2.2	977
563	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. *Journal of Clinical Oncology*, **2000**, 18, 547-61	2.2	616
562	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. *Blood*, **2007**, 109, 52-7	2.2	577
561	Ponatinib in refractory Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2012**, 367, 2075-88	59.2	556
560	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. *Journal of Clinical Investigation*, **2011**, 121, 396-409	15.9	555
559	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. *Journal of Clinical Oncology*, **2016**, 34, 2333-40	2.2	485
558	Molecular biology of bcr-abl1-positive chronic myeloid leukemia. *Blood*, **2009**, 113, 1619-30	2.2	482
557	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. *Cancer*, **2006**, 106, 1090-8	6.4	478
556	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer*, **2004**, 101, 2788-801	6.4	461
555	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. *Blood*, **2004**, 103, 4396-407	2.2	458
554	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2018**, 36, 2684-2692	2.2	446

553	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). *Blood*, **2012**, 119, 1123-9	2.2	435
552	Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. *New England Journal of Medicine*, **2019**, 381, 1728-1740	59.2	413
551	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood*, **2007**, 109, 3207-13	2.2	354
550	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. *Blood*, **2011**, 118, 4567-76	2.2	345
549	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. *Blood*, **2004**, 103, 2873-8	2.2	344
548	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. *Journal of Clinical Oncology*, **2012**, 30, 3486-92	2.2	334
547	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood*, **2014**, 123, 494-500	2.2	309
546	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. *Lancet Oncology, The*, **2017**, 18, 1061-1075	21.7	305
545	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2010**, 28, 3880-9	2.2	299
544	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 1856-62	2.2	298
543	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood*, **2013**, 121, 4655-62	2.2	296
542	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. *Blood*, **2011**, 117, 1141-5	2.2	296
541	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. *Journal of the National Cancer Institute*, **2008**, 100, 184-98	9.7	295
540	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). *Blood*, **2006**, 108, 1497-503	2.2	287
539	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*, **2019**, 33, 379-389	10.7	287
538	Acute myeloid leukaemia. *Lancet, The*, **2018**, 392, 593-606	40	280
537	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood*, **2010**, 116, 4422-9	2.2	280
536	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. *Journal of Clinical Oncology*, **2013**, 31, 3681-7	2.2	278

535	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. *Blood*, **2003**, 101, 473-5	2.2	273
534	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. *Journal of Clinical Oncology*, **2005**, 23, 3948-56	2.2	259
533	The effects of imatinib on pregnancy outcome. *Blood*, **2008**, 111, 5505-8	2.2	256
532	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood*, **2002**, 99, 3547-53	2.2	251
531	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. *Blood*, **2012**, 119, 1981-7	2.2	249
530	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. *Blood*, **2007**, 110, 4005-11	2.2	247
529	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood*, **2012**, 119, 3403-12	2.2	242
528	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. *Clinical Cancer Research*, **2005**, 11, 3425-32	12.9	237
527	Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. *Journal of Clinical Oncology*, **2010**, 28, 424-30	2.2	235
526	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. *Cancer Cell*, **2014**, 26, 428-442	24.3	233
525	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. *Journal of Clinical Oncology*, **2011**, 29, 4417-23	2.2	230
524	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. *Cancer Discovery*, **2019**, 9, 370-383	24.4	228
523	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood*, **2018**, 132, 393-404	2.2	221
522	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. *Journal of Clinical Oncology*, **2018**, 36, 231-237	2.2	220
521	Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. *Journal of Clinical Oncology*, **2010**, 28, 392-7	2.2	204
520	Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. *Cancer*, **2003**, 98, 522-8	6.4	200
519	Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 398-404	2.2	198
518	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. *Cancer*, **2010**, 116, 3830-4	6.4	195

517	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. *Blood*, **2003**, 101, 1692-7	2.2	193
516	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. *Blood*, **2017**, 129, 572-581	2.2	191
515	Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. *Cancer*, **2003**, 97, 1033-41	6.4	190
514	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncology, The*, **2015**, 16, 1547-1555	21.7	188
513	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Cancer*, **2012**, 118, 3123-7	6.4	187
512	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. *British Journal of Haematology*, **2007**, 136, 624-7	4.5	187
511	Pregnancy among patients with chronic myeloid leukemia treated with imatinib. *Journal of Clinical Oncology*, **2006**, 24, 1204-8	2.2	183
510	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. *Blood*, **2003**, 101, 3794-800	2.2	183
509	Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin All-Trans Retinoic Acid Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **1999**, 93, 2478-2484	2.2	183
508	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 984-997	21.7	182
507	Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. *Blood*, **2006**, 108, 1835-40	2.2	181
506	Phase I study of bortezomib in refractory or relapsed acute leukemias. *Clinical Cancer Research*, **2004**, 10, 3371-6	12.9	179
505	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. *Blood*, **2014**, 123, 94-100	2.2	175
504	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. *Blood*, **2008**, 111, 1039-43	2.2	175
503	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. *Blood*, **2012**, 120, 4840-5	2.2	169
502	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. *Blood*, **2003**, 102, 83-6	2.2	164
501	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 612-21	21.7	164
500	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. *Cancer*, **2007**, 109, 1133-7	6.4	158

499	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. *Lancet Haematology,the*, **2015**, 2, e186-93	14.6	153
498	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. *Haematologica*, **2011**, 96, 62-8	6.6	150
497	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2018** , 19, 889-903	21.7	145
496	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. *Blood*, **2009**, 113, 3938-46	2.2	144
495	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. *Blood*, **2004**, 104, 1979-88	2.2	144
494	Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. *Cancer*, **1999**, 86, 2632-41	6.4	143
493	Chronic myeloid leukemia: diagnosis and treatment. *Mayo Clinic Proceedings*, **2006**, 81, 973-88	6.4	140
492	Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. *Journal of Clinical Oncology*, **2010**, 28, 4207-13	2.2	138
491	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood*, **2014**, 123, 2317-24	2.2	137
490	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. *Haematologica*, **2014**, 99, 465-73	6.6	137
489	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. *Blood*, **2009**, 113, 6322-9	2.2	137
488	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. *British Journal of Haematology*, **2015**, 168, 69-81	4.5	136
487	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. *Blood*, **2009**, 113, 2154-60	2.2	135
486	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. *Journal of Clinical Oncology*, **2012**, 30, 2204-10	2.2	132
485	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. *Blood*, **2003**, 101, 4714-6	2.2	132
484	The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. *Cancer*, **2019**, 125, 1470-1481	6.4	132
483	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. *Blood*, **2006**, 108, 2811-3	2.2	130
482	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. *Blood*, **2009**, 113, 6315-21	2.2	129

481	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. *Blood*, **2003**, 101, 97-100	2.2	128
480	Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. *Journal of Clinical Oncology*, **1999**, 17, 284-92	2.2	126
479	Treatment of Relapsed/Refractory Acute Myeloid Leukemia. *Current Treatment Options in Oncology* , **2017**, 18, 17	5.4	124
478	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. *Journal of Clinical Oncology*, **2004**, 22, 1287-92	2.2	124
477	Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. *Cancer*, **2015**, 121, 234-42	6.4	123
476	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. *Cancer*, **2002**, 94, 1492-9	6.4	123
475	Chronic myelogenous leukemia: a review. *American Journal of Medicine*, **1996**, 100, 555-70	2.4	123
474	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. *Journal of Hematology and Oncology*, **2019**, 12, 1	22.4	119
473	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. *Blood*, **2003**, 102, 4527-34	2.2	117
472	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood*, **2011**, 118, 4541-6; quiz 4759	2.2	115
471	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. *Cancer*, **2007**, 109, 899-906	6.4	115
470	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *American Journal of Hematology*, **2015**, 90, 276-81	7.1	114
469	Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood*, **2007**, 110, 2991-5	2.2	114
468	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. *Cancer*, **2003**, 98, 1905-11	6.4	114
467	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. *New England Journal of Medicine*, **2019**, 381, 2315-2326	59.2	114
466	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. *Blood*, **2008**, 111, 1774-80	2.2	112
465	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. *Blood*, **2008**, 112, 53-5	2.2	111
464	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. *Blood*, **2013**, 121, 4867-74	2.2	110

463	Imatinib and beyond--exploring the full potential of targeted therapy for CML. *Nature Reviews Clinical Oncology*, **2009**, 6, 535-43	19.4	110
462	Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. *Cancer*, **1995**, 76, 2393-417	6.4	110
461	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. *Cancer*, **2007**, 109, 248-55	6.4	108
460	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. *Blood*, **2009**, 114, 4361-8	2.2	107
459	Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. *Cancer*, **2003**, 97, 2218-24	6.4	106
458	Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. *Cancer*, **2016**, 122, 3650-3656	6.4	105
457	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. *Lancet Haematology,the*, **2018**, 5, e618-e627	14.6	105
456	Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. *Leukemia Research*, **2002**, 26, 881-4	2.7	104
455	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. *Blood*, **2009**, 114, 2037-43	2.2	103
454	Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. *Cancer*, **2008**, 113, 985-94	6.4	103
453	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. *Blood*, **2014**, 123, 1309-18	2.2	102
452	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. *Cancer*, **2009**, 115, 5382-93	6.4	102
451	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 897-901	2	101
450	Current and emerging treatment options in chronic myeloid leukemia. *Cancer*, **2007**, 109, 2171-81	6.4	101
449	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. *Blood*, **2012**, 120, 2573-80	2.2	100
448	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 89-97	4.7	99
447	Nilotinib-associated vascular events. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 337-40	2	99
446	High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. *Journal of Clinical Oncology*, **2009**, 27, 4754-9	2.2	99

445	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. *Cancer*, **2009**, 115, 2482-90	6.4	98
444	Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. *American Journal of Hematology*, **2016**, 91, 869-74	7.1	98
443	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2009**, 115, 551-60	6.4	97
442	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. *Cancer*, **2004**, 100, 116-21	6.4	97
441	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Blood*, **2016**, 127, 2742-50	2.2	97
440	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. *Cancer*, **2010**, 116, 3852-61	6.4	96
439	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. *Cancer*, **2003**, 97, 2760-6	6.4	96
438	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. *Science Translational Medicine*, **2016**, 8, 355ra117	17.5	93
437	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. *Blood*, **2005**, 105, 2281-6	2.2	92
436	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. *Cancer*, **2008**, 112, 837-45	6.4	91
435	Secondary mutations as mediators of resistance to targeted therapy in leukemia. *Blood*, **2015**, 125, 3236-45	2.2	90
434	Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. *Cancer*, **2014**, 120, 2142-9	6.4	88
433	How I treat newly diagnosed chronic phase CML. *Blood*, **2012**, 120, 1390-7	2.2	88
432	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. *Cancer*, **2010**, 116, 5568-74	6.4	88
431	Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. *Blood*, **2008**, 112, 516-8	2.2	88
430	The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. *Cancer*, **2006**, 107, 1918-29	6.4	88
429	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. *Leukemia Research*, **2016**, 48, 84-91	2.7	88
428	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. *Blood*, **2016**, 127, 1269-75	2.2	87

427	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. *Lancet Haematology,the*, **2015**, 2, e339-46	14.6	86
426	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. *Cancer*, **2009**, 115, 3709-18	6.4	86
425	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. *Leukemia Research* , **2010**, 34, 752-6	2.7	85
424	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. *Clinical Cancer Research*, **2002**, 8, 2177-87	12.9	84
423	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. *American Journal of Hematology*, **2014**, 89, 732-42	7.1	83
422	Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. *Clinical Cancer Research*, **2008**, 14, 4392-9	12.9	83
421	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. *Cancer*, **2011**, 117, 2145-55	6.4	81
420	Thalidomide therapy for myelofibrosis with myeloid metaplasia. *Cancer*, **2006**, 106, 1974-84	6.4	80
419	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2016**, 172, 392-400	4.5	79
418	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. *Leukemia and Lymphoma*, **2013**, 54, 1411-7	1.9	79
417	Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. *Blood*, **2015**, 126, 222-32	2.2	79
416	Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. *Cancer*, **2006**, 106, 1306-15	6.4	78
415	Important therapeutic targets in chronic myelogenous leukemia. *Clinical Cancer Research*, **2007**, 13, 1089-97	12.9	78
414	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. *Blood*, **2006**, 108, 1421-3	2.2	77
413	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. *American Journal of Hematology*, **2014**, 89, 947-53	7.1	76
412	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. *Cancer*, **2017**, 123, 4391-4402	6.4	76
411	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. *Haematologica*, **2012**, 97, 731-8	6.6	76
410	Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. *Journal of Clinical Oncology*, **2009**, 27, 3642-9	2.2	76

409	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. *Clinical Cancer Research*, **2018**, 24, 2294-2303	12.9	75
408	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. *American Journal of Hematology*, **2018**, 93, 1301-1310	7.1	75
407	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. *Cancer*, **2007**, 109, 1556-60	6.4	75
406	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nature Communications*, **2020**, 11, 5327	17.4	75
405	The impact of dasatinib on pregnancy outcomes. *American Journal of Hematology*, **2015**, 90, 1111-5	7.1	74
404	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. *Cancer*, **2008**, 113, 1933-52	6.4	74
403	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. *Blood*, **2011**, 118, 4353-8	2.2	73
402	Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. *Blood*, **2002**, 99, 2265-7	2.2	73
401	Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. *Journal of Clinical Oncology*, **2000**, 18, 3513-21	2.2	73
400	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. *Blood*, **2013**, 122, 641-7	2.2	72
399	Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. *Cancer*, **2007**, 109, 1355-9	6.4	72
398	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. *Clinical Cancer Research*, **2002**, 8, 2167-76	12.9	72
397	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. *Lancet Haematology,the*, **2015**, 2, e376-83	14.6	71
396	Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 524-31	2.2	70
395	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. *British Journal of Haematology*, **2004**, 125, 187-95	4.5	70
394	High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. *Cancer*, **2001**, 92, 1999-2015	6.4	70
393	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). *Cancer*, **2014**, 120, 3660-8	6.4	69
392	Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 515-29	3	69

391	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. *Blood*, **2008**, 112, 4839-42	2.2	68
390	Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. *Clinical Cancer Research*, **2014**, 20, 1735-40	12.9	67
389	Clonal evolution in chronic myelogenous leukemia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 671-84, x	3.1	67
388	Central nervous system relapse in adults with acute lymphoblastic leukemia. *Cancer*, **2002**, 94, 773-9	6.4	67
387	Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 530-3	2	66
386	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2015**, 87, 346-56	4.6	65
385	Natural history and staging of chronic myelogenous leukemia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 569-84, viii	3.1	65
384	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. *Blood*, **1999**, 93, 2075-2080	2.2	65
383	Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?. *Journal of Clinical Oncology*, **2011**, 29, 4260-5	2.2	63
382	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. *Nature Communications*, **2019**, 10, 244	17.4	63
381	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. *Haematologica*, **2012**, 97, 1029-35	6.6	62
380	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. *Cancer*, **2003**, 98, 888-93	6.4	62
379	Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. *Cancer*, **2009**, 115, 3217-21	6.4	61
378	Chronic myelogenous leukemia: a review and update of therapeutic strategies. *Cancer*, **2003**, 98, 437-57	6.4	61
377	Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. *American Journal of Hematology*, **2016**, 91, 606-16	7.1	61
376	Chronic myeloid leukemia: reminiscences and dreams. *Haematologica*, **2016**, 101, 541-58	6.6	61
375	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. *American Journal of Hematology*, **2019**, 94, 346-357	7.1	61
374	Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. *Cancer*, **2006**, 106, 346-52	6.4	60

373	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, 213-221	7.1	59
372	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. *American Journal of Hematology*, **2015**, 90, 755-68	7.1	58
371	Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. *Cancer*, **2002**, 94, 2024-32	6.4	58
370	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. *Cancer*, **2017**, 123, 2875-2880	6.4	57
369	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. *Cancer*, **2007**, 110, 340-4	6.4	57
368	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. *Cancer*, **2005**, 103, 2099-108	6.4	57
367	Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. *Mayo Clinic Proceedings*, **2015**, 90, 1440-54	6.4	56
366	Hedgehog signaling inhibitors in solid and hematological cancers. *Cancer Treatment Reviews*, **2019**, 76, 41-50	14.4	55
365	Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. *American Journal of Hematology*, **2016**, 91, 1206-1214	7.1	55
364	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. *American Journal of Hematology*, **2013**, 88, 1024-9	7.1	55
363	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Advances*, **2017**, 1, 1312-1323	7.8	55
362	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. *American Journal of Hematology*, **2018**, 93, 1136-1141	7.1	54
361	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. *Blood*, **2011**, 117, 1822-7	2.2	54
360	Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. *Cancer*, **2012**, 118, 5811-8	6.4	53
359	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. *Blood*, **2006**, 107, 480-2	2.2	53
358	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. *Cancer*, **2004**, 100, 2592-7	6.4	53
357	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. *Lancet Haematology,the*, **2015**, 2, e118-28	14.6	52
356	Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. *Journal of Clinical Oncology*, **2009**, 27, 3659-63	2.2	52

355	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. *Blood*, **2011**, 117, 3641-7	2.2	51
354	Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. *Cancer*, **2009**, 115, 3924-34	6.4	50
353	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. *Blood*, **2012**, 119, 4524-6	2.2	49
352	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. *Blood*, **2011**, 117, 5600-6	2.2	49
351	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. *Clinical Cancer Research*, **2004**, 10, 68-75	12.9	49
350	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. *Blood Advances*, **2019**, 3, 851-861	7.8	49
349	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Cancer*, **2015**, 121, 3894-904	6.4	47
348	Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. *Cancer*, **2009**, 115, 2912-21	6.4	47
347	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. *Cancer*, **1995**, 75, 464-70	6.4	47
346	Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. *Cancer*, **2011**, 117, 897-906	6.4	46
345	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. *Cancer*, **2007**, 110, 1295-302	6.4	46
344	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. *Mayo Clinic Proceedings*, **2005**, 80, 390-402	6.4	46
343	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *Journal of Clinical Oncology*, **2016**, 34, 1864-71	2.2	46
342	New targeted approaches in chronic myeloid leukemia. *Journal of Clinical Oncology*, **2005**, 23, 6316-24	2.2	45
341	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. *Cancer*, **2011**, 117, 4869-4877	6.4	44
340	Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. *Leukemia and Lymphoma*, **2010**, 51, 778-82	1.9	44
339	Treatment selection after imatinib resistance in chronic myeloid leukemia. *Targeted Oncology*, **2009** , 4, 3-10	5	44
338	Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. *Journal of Clinical Oncology*, **2005**, 23, 2805-12	2.2	44

337	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. *Cancer*, **2014**, 120, 373-80	6.4	43
336	Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 78-82	2	43
335	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. *Haematologica*, **2015**, 100, 898-904	6.6	43
334	Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. *Cancer*, **2007**, 109, 907-14	6.4	43
333	A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. *Cancer*, **2003**, 97, 1234-41	6.4	43
332	Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 584-91	2	42
331	Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. *Blood*, **2015**, 126, 1699-706	2.2	42
330	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. *American Journal of Hematology*, **2015**, 90, E66-72	7.1	42
329	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. *Blood*, **2013**, 122, 2807-11; quiz 2920	2.2	42
328	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?. *Cancer*, **2011**, 117, 3293-304	6.4	42
327	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. *Cancer*, **2010**, 116, 2673-81	6.4	42
326	High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. *Cancer*, **2001**, 92, 7-14	6.4	42
325	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. *Cancer*, **2011**, 117, 572-80	6.4	41
324	Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. *Cancer*, **2009**, 115, 1381-94	6.4	40
323	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. *Leukemia and Lymphoma*, **2007**, 48, 283-9	1.9	40
322	All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. *Cancer*, **1994**, 73, 2946-52	6.4	40
321	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. *Cancer*, **2017**, 123, 3050-3060	6.4	39
320	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. *Cancer*, **2017**, 123, 459-467	6.4	39

319	Disruption of Wnt/Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in -Mutant Acute Myeloid Leukemia. *Clinical Cancer Research*, **2018**, 24, 2417-2429	12.9	38
318	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. *Haematologica*, **2019**, 104, 93-101	6.6	38
317	Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. *Cancer*, **2007**, 110, 2000-6	6.4	38
316	Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. *Cancer*, **2015**, 121, 1637-44	6.4	37
315	Evolution of therapies for chronic myelogenous leukemia. *Cancer Journal (Sudbury, Mass.)*, **2011**, 17, 465-76	2.6	37
314	Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. *Cancer*, **2008**, 112, 2112-8	6.4	37
313	Advanced-phase chronic myeloid leukemia. *Seminars in Hematology*, **2003**, 40, 79-86	4	37
312	Advanced-phase chronic myeloid leukemia. *Seminars in Hematology*, **2003**, 40, 79-86	4	37
311	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. *Cancer*, **2012**, 118, 2665-73	6.4	36
310	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer*, **2019**, 125, 2579-2586	6.4	35
309	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. *Leukemia Research*, **2015**, 39, 1367-74	2.7	35
308	Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 155-162.e1	2	35
307	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. *Scientific Reports*, **2017**, 7, 11253	4.9	35
306	First-line therapy for chronic myeloid leukemia: Past, present, and future. *American Journal of Hematology*, **2009**, 84, 287-93	7.1	35
305	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. *Cancer*, **2010**, 116, 1419-30	6.4	35
304	AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.. *Blood*, **2009**, 114, 636-636	2.2	35
303	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. *Blood*, **2014**, 124, 3135-3135	2.2	35
302	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. *British Journal of Cancer*, **2018**, 118, 1425-1433	8.7	35

301	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. *British Journal of Haematology*, **2010**, 150, 303-12	4.5	34
300	New agents in acute myeloid leukemia and other myeloid disorders. *Cancer*, **2004**, 100, 441-54	6.4	34
299	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 465-465	2.2	34
298	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. *Blood*, **2019**, 133, 2348-2351	2.2	33
297	Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. *Lancet Oncology, The*, **2013**, 14, 354-62	21.7	33
296	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. *Blood*, **2017**, 130, 2084-2091	2.2	33
295	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. *Cancer*, **2009**, 115, 3935-43	6.4	33
294	The biology of chronic myelogenous leukemia: implications for imatinib therapy. *Seminars in Hematology*, **2007**, 44, S4-14	4	33
293	Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. *British Journal of Haematology*, **2016**, 172, 97-110	4.5	33
292	Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer*, **2018**, 124, 2740-2747	6.4	32
291	Chronic myeloid leukemia: overview of new agents and comparative analysis. *Current Treatment Options in Oncology*, **2013**, 14, 127-43	5.4	32
290	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. *Journal of Translational Medicine*, **2015**, 13, 294	8.5	32
289	Targeted therapy in chronic myeloid leukemia. *Expert Review of Anticancer Therapy*, **2008**, 8, 99-110	3.5	32
288	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2004**, 100, 2396-402	6.4	32
287	Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. *Cancer*, **2001**, 92, 2016-22	6.4	32
286	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. *Journal of Hematology and Oncology*, **2018**, 11, 143	22.4	32
285	Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?. *Mayo Clinic Proceedings*, **2009**, 84, 161-169	6.4	31
284	Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. *Leukemia and Lymphoma*, **1996**, 21, 85-92	1.9	31

283	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. *Lancet Haematology,the*, **2016**, 3, e581-e591	14.6	30
282	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. *Blood Reviews*, **2014**, 28, 179-87	11.1	30
281	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. *Cancer*, **2017**, 123, 4430-4439	6.4	30
280	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Cancer*, **2011**, 117, 1236-44	6.4	30
279	Homoharringtonine for the treatment of chronic myelogenous leukemia. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 1029-37	4	30
278	Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. *Leukemia and Lymphoma*, **2004**, 45, 2187-95	1.9	30
277	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. *Haematologica*, **2018**, 103, 1298-1307	6.6	30
276	A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 223-30	2	29
275	Accelerated and blastic phases of chronic myelogenous leukemia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 753-74, xii	3.1	29
274	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *American Journal of Hematology*, **2016**, 91, 227-32	7.1	29
273	Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. *American Journal of Hematology*, **2015**, 90, 27-30	7.1	28
272	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. *Lancet Haematology,the*, **2018**, 5, e136-e146	14.6	28
271	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. *Leukemia and Lymphoma*, **2014**, 55, 1451-62	1.9	28
270	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. *Blood*, **2008**, 112, 5190-2	2.2	28
269	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. *Expert Opinion on Investigational Drugs*, **2007**, 16, 679-87	5.9	28
268	Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. *Current Molecular Medicine*, **2005**, 5, 615-23	2.5	28
267	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. *Investigational New Drugs*, **1999**, 17, 89-95	4.3	28
266	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. *Oncotarget*, **2015**, 6, 30487-99	3.3	28

265	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 767-775	4.7	27
264	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. *Future Oncology*, **2019**, 15, 3531-3545	3.6	27
263	First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. *American Journal of Hematology*, **2017**, 92, 1214-1223	7.1	27
262	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. *Cancer*, **2012**, 118, 5283-92	6.4	27
261	Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 286-96	2	27
260	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. *British Journal of Haematology*, **2015**, 171, 471-7	4.5	26
259	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 684-695.e6	2	25
258	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. *Leukemia and Lymphoma*, **2015**, 56, 120-7	1.9	25
257	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. *Expert Opinion on Investigational Drugs*, **2014**, 23, 943-54	5.9	25
256	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. *Leukemia and Lymphoma*, **2014**, 55, 2879-86	1.9	25
255	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. *Cancer*, **2016**, 122, 238-48	6.4	24
254	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. *Cancer*, **2019**, 125, 3755-3766	6.4	24
253	Molecular targeted therapy in acute myeloid leukemia. *Hematology*, **2012**, 17 Suppl 1, S59-62	2.2	24
252	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?. *Current Oncology Reports*, **2010**, 12, 302-13	6.3	24
251	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. *Acta Haematologica*, **2020**, 143, 567-573	2.7	24
250	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. *American Journal of Hematology*, **2018**, 93, 84-90	7.1	23
249	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. *Core Evidence*, **2010**, 4, 207-13	4.9	23
248	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. *Leukemia and Lymphoma*, **2008**, 49, 1399-402	1.9	23

247	New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. *Seminars in Hematology*, **2007**, 44, S25-31	4	23
246	Leukemia cells eat their VEGFtables. *Blood*, **2002**, 100, 4256-4256	2.2	23
245	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. *Blood*, **2021**, 138, 2031-2041	2.2	23
244	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. *American Journal of Hematology*, **2019**, 94, 984-991	7.1	22
243	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. *Journal of Hematology and Oncology*, **2015**, 8, 32	22.4	22
242	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	22
241	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. *Haematologica*, **2013**, 98, 1686-8	6.6	22
240	Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. *Clinical Lymphoma and Myeloma*, **2007**, 7 Suppl 3, S105-12		22
239	Advances in the therapy of chronic idiopathic myelofibrosis. *Oncologist*, **2006**, 11, 929-43	5.7	22
238	Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. *Cancer*, **2004**, 100, 2064-78	6.4	22
237	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. *Cancer*, **2005**, 104, 777-80	6.4	22
236	Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. *Leukemia and Lymphoma*, **2016**, 57, 237-9	1.9	21
235	New treatment for acute myelogenous leukemia. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 95-106	4	21
234	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 213-222.e2	2	21
233	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. *Cancer*, **2012**, 118, 418-27	6.4	21
232	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 1599-607	3.5	21
231	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. *Seminars in Oncology*, **2008**, 35, S1-17; quiz S18-20	5.5	21
230	Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. *Future Oncology*, **2008**, 4, 611-21	3.6	21

229	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. *Current Opinion in Oncology*, **2006**, 18, 578-83	4.2	21
228	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Cancer*, **2003**, 97, 2225-8	6.4	21
227	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. *American Journal of Hematology*, **2015**, 90, 769-73	7.1	20
226	Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. *Expert Opinion on Drug Delivery*, **2015**, 12, 1107-20	8	20
225	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. *Cancer*, **2010**, 116, 3631-7	6.4	20
224	New strategies in chronic myeloid leukemia. *International Journal of Hematology*, **2006**, 83, 289-93	2.3	20
223	Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 477-84	2	19
222	Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. *British Journal of Haematology*, **2013**, 161, 659-66	4.5	19
221	Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). *Cancer*, **2010**, 116, 4991-5000	6.4	19
220	Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. *Clinical Cancer Research*, **2008**, 14, 509-14	12.9	19
219	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. *Cancer*, **2001**, 92, 2501-7	6.4	19
218	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. *Lancet Haematology,the*, **2021**, 8, e481-e491	14.6	19
217	Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. *Expert Review of Anticancer Therapy*, **2013**, 13, 1433-52	3.5	18
216	Ponatinib in Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2014**, 370, 577	59.2	18
215	The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 302-6	2	18
214	Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. *Clinical Lymphoma and Myeloma*, **2008**, 8 Suppl 3, S82-8		18
213	Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy. *Blood*, **1999**, 93, 3149-3150	2.2	18
212	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. *Blood*, **2019**, 134, 231-231	2.2	18

211	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 152-62	2	17
210	Monitoring molecular response in chronic myeloid leukemia. *Cancer*, **2011**, 117, 1113-22	6.4	17
209	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. *Cancer*, **2011**, 117, 327-35	6.4	17
208	Third-generation tyrosine kinase inhibitors and beyond. *Seminars in Hematology*, **2010**, 47, 371-80	4	17
207	Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. *Haematologica*, **2007**, 92, 170-5	6.6	17
206	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. *Leukemia Research*, **2005**, 29, 649-52	2.7	17
205	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. *Journal of Hematology and Oncology*, **2020**, 13, 92	22.4	17
204	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. *American Journal of Hematology*, **2019**, 94, 46-54	7.1	17
203	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. *Cancer Medicine*, **2018**, 7, 5457-5469	4.8	17
202	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. *Haematologica*, **2017**, 102, 519-528	6.6	16
201	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. *British Journal of Haematology*, **2019**, 187, 543-545	4.5	16
200	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. *American Journal of Hematology*, **2015**, 90, 1065-70	7.1	16
199	Overcoming drug resistance in chronic myeloid leukemia. *Current Opinion in Hematology*, **2006**, 13, 79-86	3.3	16
198	Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. *Seminars in Hematology*, **2002**, 39, 26-30	4	16
197	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 42-50	13.4	16
196	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. *Leukemia Research*, **2015**, 39, 822-7	2.7	15
195	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 163-8.e1-2	2	15
194	Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. *Journal of Clinical Oncology*, **2014**, 32, 3077	2.2	15

193	Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. *Cancer*, **2010**, 116, 3152-9	6.4	15
192	Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. *Clinical Lymphoma and Myeloma*, **2003**, 4 Suppl 1, S30-5		15
191	Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2014**, 32, 7027-7027	2.2	15
190	Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. *Blood Cancer Discovery*, **2020**, 1, 134-145	7	15
189	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *International Journal of Hematology*, **2019**, 109, 545-552	2.3	14
188	Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2018**, 124, 1160-1168	6.4	14
187	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1390-8	4.7	14
186	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. *British Journal of Haematology*, **2019**, 185, 595-598	4.5	14
185	Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. *Cancer*, **2018**, 124, 587-595	6.4	14
184	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. *American Journal of Hematology*, **2019**, 94, 1388-1395	7.1	13
183	Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). *American Journal of Hematology*, **2017**, 92, E3-E4	7.1	13
182	Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. *Haematologica*, **2015**, 100, e494-5	6.6	13
181	The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. *Cancer*, **2008**, 113, 1338-43	6.4	13
180	Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. *Blood*, **2020**, 136, 47-50	2.2	13
179	Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. *Mayo Clinic Proceedings*, **2009**, 84, 161-9	6.4	13
178	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. *American Journal of Hematology*, **2020**, 95, 144-150	7.1	13
177	Improving attribution of adverse events in oncology clinical trials. *Cancer Treatment Reviews*, **2019**, 76, 33-40	14.4	12
176	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. *American Journal of Hematology*, **2019**, 94, E158-E160	7.1	12

175	Long-term results of frontline dasatinib in chronic myeloid leukemia. *Cancer*, **2020**, 126, 1502-1511	6.4	12
174	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. *British Journal of Haematology*, **2016**, 173, 114-26	4.5	12
173	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. *Annals of Hematology*, **2017**, 96, 1303-1313	3	12
172	Treatment options for chronic myeloid leukemia. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 815-28	4	12
171	The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 421-6	2	12
170	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. *Cancer*, **2011**, 117, 5085-93	6.4	12
169	Imatinib mesylate in the treatment of chronic myelogenous leukemia. *International Journal of Hematology*, **2004**, 79, 411-9	2.3	12
168	Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. *Blood*, **2019**, 134, 674-674	2.2	12
167	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. *Blood*, **2020**, 136, 41-42	2.2	12
166	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2546-2546	2.2	12
165	Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. *Blood*, **2016**, 128, 625-625	2.2	12
164	Third-line therapy for chronic myeloid leukemia: current status and future directions. *Journal of Hematology and Oncology*, **2021**, 14, 44	22.4	12
163	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1589-1599	4.9	11
162	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. *BMC Cancer* , **2018**, 18, 359	4.8	11
161	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2016**, 122, 3336-3343	6.4	11
160	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. *Cancer Medicine*, **2019**, 8, 6559-6565	4.8	11
159	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. *Cancer*, **2011**, 117, 982-91	6.4	11
158	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. *Cancer Science*, **2010**, 101, 2005-10	6.9	11

157	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1127-36	5.9	11
156	Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.. *Journal of Clinical Oncology*, **2018**, 36, 7002-7002	2.2	11
155	CMML: a biologically distinct myeloproliferative disease. *Psychophysiology*, **2003**, 2, 202-8		11
154	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. *Leukemia*, **2020**, 34, 2064-2073	10.7	10
153	A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. *European Journal of Cancer Care*, **2013**, 22, 605-11	2.4	10
152	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S261-5		10
151	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. *Targeted Oncology*, **2006**, 1, 186-196	5	10
150	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. *Blood*, **2018**, 132, 790-790	2.2	10
149	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥ Tyrosine Kinase Inhibitors (TKIs. *Blood*, **2020**, 136, LBA-4-LBA-4	2.2	10
148	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. *American Journal of Hematology*, **2020**, 95, 1288-1295	7.1	10
147	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. *Haematologica*, **2021**, 106, 2121-2130	6.6	10
146	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. *Journal of Clinical Pharmacology*, **2019**, 60, 605	2.9	10
145	Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. *American Journal of Hematology*, **2021**, 96, 493-507	7.1	10
144	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. *Blood*, **2021**, 138, 2042-2050	2.2	10
143	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. *Leukemia and Lymphoma*, **2018**, 59, 1312-1322	1.9	9
142	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 552-8	4.7	9
141	Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. *Expert Opinion on Investigational Drugs*, **2014**, 23, 265-72	5.9	9
140	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?. *Current Oncology Reports*, **2009**, 11, 337-45	6.3	9

139	Clinical activity of tipifarnib in hematologic malignancies. *Expert Opinion on Investigational Drugs*, **2007**, 16, 381-92	5.9	9
138	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).. *Blood*, **2005**, 106, 37-37	2.2	9
137	Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. *Journal of Clinical Oncology*, **2017**, 35, 7051-7051	2.2	9
136	Chronic myeloid leukemia: sequencing of TKI therapies. *Hematology American Society of Hematology Education Program*, **2016**, 2016, 164-169	3.1	9
135	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 509-515.e1	2	8
134	Current practices in the management of chronic myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 48-54	2	8
133	Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 2381-95	4	8
132	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. *Blood*, **2020**, 136, 51-52	2.2	8
131	Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.. *Journal of Clinical Oncology*, **2020**, 38, 7502-7502	2.2	8
130	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. *Annals of Hematology*, **2021**, 100, 1181-1194	3	8
129	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. *Blood Advances*, **2021**, 5, 1719-1728	7.8	8
128	A second-generation TKI should always be used as initial therapy for CML. *Blood Advances*, **2018**, 2, 3653-3655	7.8	8
127	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. *British Journal of Haematology*, **2021**, 195, 378-387	4.5	8
126	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. *International Journal of Hematology*, **2018**, 107, 689-695	2.3	7
125	Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 1977-86	4	7
124	The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. *Haematologica*, **2013**, 98, e131	6.6	7
123	Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S272-9		7
122	Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. *Expert Opinion on Investigational Drugs*, **2007**, 16, 547-57	5.9	7

121	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. *Blood*, **2019**, 134, 1638-1638	2.2	7
120	Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies: Initial Safety and Efficacy. *Blood*, **2019**, 134, 4158-4158	2.2	7
119	Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.. *Journal of Clinical Oncology*, **2020**, 38, 7509-7509	2.2	7
118	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. *Leukemia and Lymphoma*, **2020**, 61, 631-640	1.9	7
117	Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. *Journal of Hematology and Oncology*, **2020**, 13, 137	22.4	7
116	Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. *American Journal of Hematology*, **2020**, 95, 1296-1303	7.1	7
115	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. *American Journal of Hematology*, **2021**, 96, 1000-1007	7.1	7
114	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. *International Journal of Hematology*, **2021**, 113, 92-99	2.3	7
113	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, e871-e882	2	6
112	Numb chin syndrome by precursor B acute lymphoblastic leukemia. *American Journal of Hematology* , **2014**, 89, 860-1	7.1	6
111	Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 693-9	2	6
110	Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. *British Journal of Haematology*, **2004**, 124, 727-38	4.5	6
109	Investigational strategies in chronic myelogenous leukemia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 619-39, ix	3.1	6
108	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. *Blood*, **2018**, 132, 3005-3005	2.2	6
107	Pregnancy Outcomes in Patients Treated with Bosutinib. *Blood*, **2018**, 132, 1729-1729	2.2	6
106	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. *Blood*, **2007**, 110, 283-283	2.2	6
105	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. *Blood*, **2012**, 120, 915-915	2.2	6
104	Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 7012-7012	2.2	6

103	How to manage CML patients with comorbidities. *Blood*, **2020**, 136, 2507-2512	2.2	6
102	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. *American Journal of Hematology*, **2021**, 96, 241-250	7.1	6
101	Chronic myeloid leukaemia. *Lancet, The*, **2021**, 398, 1914-1926	40	6
100	Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. *Haematologica*, **2013**, 98, e141-2	6.6	5
99	del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. *Cancer Genetics and Cytogenetics*, **2009**, 192, 18-23		5
98	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. *Leukemia and Lymphoma*, **2011**, 52, 1010-6	1.9	5
97	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. *Blood*, **2007**, 110, 577-577	2.2	5
96	Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).. *Journal of Clinical Oncology*, **2015**, 33, 7047-7047	2.2	5
95	Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.. *Journal of Clinical Oncology*, **2017**, 35, 7002-7002	2.2	5
94	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).. *Journal of Clinical Oncology*, **2020**, 38, 7512-7512	2.2	5
93	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. *Haematologica*, **2021**, 106, 2853-2858	6.6	5
92	Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. *Leukemia and Lymphoma*, **2020**, 61, 3120-3127	1.9	5
91	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. *Cancer* , **2021**, 127, 2641-2647	6.4	5
90	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. *Journal of Hematology and Oncology*, **2021**, 14, 94	22.4	5
89	Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. *Leukemia and Lymphoma*, **2020**, 61, 98-107	1.9	5
88	Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. *Cancer*, **2020**, 126, 1448-1459	6.4	5
87	Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6 Suppl 2, S22-S30	7.3	5
86	Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1-6	1.9	4

85	Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, S231	2	4
84	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. *Leukemia and Lymphoma*, **2019**, 60, 2384-2393	1.9	4
83	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. *Haematologica*, **2016**, 101, e324-7	6.6	4
82	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. *Leukemia and Lymphoma*, **2010**, 51, 1478-84	1.9	4
81	Standard management of patients with chronic myeloid leukemia. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 4, S382-90		4
80	Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy,. *Blood*, **2011**, 118, 3771-3771	2.2	4
79	Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. *Blood*, **2016**, 128, 1921-1921	2.2	4
78	Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.. *Journal of Clinical Oncology*, **2018**, 36, TPS7073-TPS7073	2.2	4
77	A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. *Cancer*, **2020**, 126, 4315-4321	6.4	4
76	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 338-344	2	4
75	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. *Leukemia and Lymphoma*, **2021**, 62, 224-228	1.9	4
74	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. *Blood Cancer Journal*, **2021**, 11, 60	7	4
73	Addressing financial toxicity in oncology care. *Journal of Hospital Management and Health Policy*, **2021**, 5,	0.5	4
72	Treatment-free remission in chronic myeloid leukemia. *Clinical Advances in Hematology and Oncology*, **2019**, 17, 686-696	0.6	4
71	Reply to K.R. Hoffman. *Journal of Clinical Oncology*, **2017**, 35, 567-568	2.2	3
70	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, S228-S229	2	3
69	How to manage CML patients with comorbidities. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 237-242	3.1	3
68	Clinical value of event-free survival in acute myeloid leukemia. *Blood Advances*, **2020**, 4, 1690-1699	7.8	3

67	Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. *American Journal of Hematology*, **2019**, 94, E256-E259	7.1	3
66	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. *Cancer*, **2017**, 123, 609-616	6.4	3
65	Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. *Leukemia and Lymphoma*, **2017**, 58, 722-725	1.9	3
64	Molecular resistance: an early indicator for treatment change?. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 79-87	2	3
63	Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. *Clinical Investigation*, **2013**, 3, 1127-1138		3
62	Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2733-2733	2.2	3
61	Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),. *Blood*, **2011**, 118, 3785-3785	2.2	3
60	Knowledge of prostate cancer among African American men: A systematic review. *Prostate*, **2021**, 81, 202-213	4.2	3
59	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. *Leukemia and Lymphoma*, **2020**, 61, 2811-2820	1.9	3
58	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. *Cancer Chemotherapy and Pharmacology*, **2020** , 86, 451-459	3.5	3
57	Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. *European Journal of Haematology*, **2021**, 106, 808-820	3.8	3
56	Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. *Current Oncology Reports*, **2021**, 23, 91	6.3	3
55	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. *JCO Oncology Practice*, **2021**, 17, e497-e505	2.3	3
54	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. *Leukemia and Lymphoma*, **2019**, 60, 3172-3180	1.9	2
53	Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. *Journal of Infection and Chemotherapy*, **2015**, 21, 663-7	2.2	2
52	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. *Leukemia*, **2020**, 34, 2914-2924	10.7	2
51	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. *American Journal of Hematology*, **2020**, 95, 1127	7.1	2
50	Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. *Clinical Lymphoma and Myeloma*, **2007**, 7 Suppl 2, S51-7		2

49	Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 382-382	2.2	2
48	Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML.. *Blood*, **2004**, 104, 812-812	2.2	2
47	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. *Blood*, **2016**, 128, 3171-3171	2.2	2
46	Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).. *Journal of Clinical Oncology*, **2019**, 37, e18515-e18515	2.2	2
45	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.. *Journal of Hematology and Oncology*, **2022**, 15, 1	22.4	2
44	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. *Leukemia and Lymphoma*, **2020**, 61, 3287-3305	1.9	2
43	Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health "All of Us" Research Program. *Cancer Medicine*, **2021**, 10, 3646-3654	4.8	2
42	Chronic Myeloid Leukemia **2016**, 1-11		2
41	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. *Leukemia and Lymphoma*, **2021**, 62, 909-917	1.9	2
40	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. *Journal of Hematology and Oncology*, **2021**, 14, 110	22.4	2
39	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. *Leukemia Research*, **2021**, 111, 106690	2.7	2
38	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.. *Blood Reviews*, **2022**, 100968	11.1	2
37	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. *American Journal of Hematology*, **2019**, 94, E188-E190	7.1	1
36	T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1. *Leukemia and Lymphoma*, **2009**, 50, 321-2	1.9	1
35	Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. *Cancer*, **1997**, 80, 396-400	6.4	1
34	Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. *Clinical Lymphoma and Myeloma*, **2008**, 8 Suppl 3, S75-81		1
33	Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Current Opinion in Internal Medicine*, **2007**, 14, 138-44		1
32	Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis. *Blood*, **2019**, 134, 2610-2610	2.2	1

31	CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. *Blood*, **2016**, 128, 1923-1923	2.2	1
30	Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. *Journal of Clinical Oncology*, **2019**, 37, 7051-7051	2.2	1
29	Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.. *Journal of Clinical Oncology*, **2020**, 38, 7525-7525	2.2	1
28	Financial distress among breast cancer survivors **2020**, 2, 48-53		1
27	Optimizing management of acute leukemia in community centers and when to refer. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 123-128	3.1	1
26	Chronic Myeloid Leukemia **2014**, 1944-1957.e2		1
25	The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. *Revista Brasileira De Hematologia E Hemoterapia*, **2011**, 33, 455-60		1
24	Financial assistance programs for cancer patients **2021**, 3, 119-123		1
23	Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 1-16	0.6	1
22	The Care of the Leukemic Patients in Times of SARS-CoV-2. *Current Oncology Reports*, **2021**, 23, 114	6.3	0
21	Problems in living among breast cancer survivors **2021**, 3, 101-109		0
20	Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.. *International Journal of Hematology*, **2022**, 1	2.3	0
19	Targeted Therapies in Chronic Myeloid Leukemia **2015**, 111-120		
18	Chronic myeloid leukemia: the race is yet to be won. *Cmaj*, **2012**, 184, 857-8	3.5	
17	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. *Expert Opinion on Orphan Drugs*, **2013**, 1, 607-623	1.1	
16	Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10 Suppl 1, S14-9	2	
15	Keeping up with rapid change. *Current Hematologic Malignancy Reports*, **2006**, 1, 1-1	4.4	
14	Optimal Therapy for Chronic Myeloid Leukemia Blast Crisis: Current Concepts. *Clinical Leukemia*, **2006**, 1, 87-94		

13	Dasatinib: A Dual ABL and SRC Inhibitor **2006**, 59-68	
12	Investigational agents in myeloid disorders. *Advances in Pharmacology*, **2004**, 51, 59-97	5.7
11	Comments on the Hammersmith policy. *Seminars in Hematology*, **2003**, 40, 105-106	4
10	Targeted Therapy in Myelodysplastic Syndrome **2008**, 237-260	
9	Targeted Therapy in Chronic Myeloid Leukemia **2008**, 87-99	
8	New Therapies for Chronic Myeloid Leukemia **2007**, 165-184	
7	New agents in chronic myelogenous leukemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2003**, 1, 501-12	7.3
6	Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results.. *Journal of Clinical Oncology*, **2020**, 38, 1574-1574	2.2
5	Chronic Myeloid Leukemia: Pathophysiology and Therapeutics **2010**, 139-153	
4	Standard Management of Patients with Chronic Myeloid Leukemia71-85	
3	New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. *Applied Immunohistochemistry and Molecular Morphology*, **2019**, 27, 33-39	1.9
2	Chronic Myeloid Leukemia **2020**, 1836-1849.e2	
1	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. *Hematologic Malignancies*, **2021**, 61-76	0